An interventional study of Sham-stimulation and Active-stimulation in Treatment Resistant Depression, sponsored by Abbott Medical Devices. Recruiting at 26 sites in United States. Open to participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 47th largest by planned enrollment of the 181 interventional ones that give a count, is one of 16 that started in 2024, is one of 72 with no phase, reaches primary completion later than 22 of the 64 other live ones, and was the 171st registered.
449 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 22 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 66 across the 23 observational. Of the 120 that completed or were terminated, 70 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 205 have an industry lead sponsor. The 10 most frequent:
This study is registered under Abbott Medical Devices, one of the names counted as Abbott. Under that name alone:
Abbott Medical Devices is the lead sponsor of 540 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
Abbott has 2 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
The aim of this prospective, multi-centered, double-blind, randomized, delayed-stimulation/ Sham-stimulation controlled 12-month study is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using the Infinity™ Deep Brain Stimulation (DBS) system as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) for adults who are experiencing a Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.
In a double-blind fashion, half the subjects will receive active DBS therapy, while half will receive sham stimulation. After the 12-month endpoint, all subjects will be unblinded to their treatment group, and subjects in the control arm will receive active DBS therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group will be implanted with DBS system but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
Device: Sham-stimulation
Group will have DBS system activated 2 weeks post-implant.
Device: Active-stimulation
Sham-stimulation
Active DBS
Change in MADRS total score
The MADRS absolute change is measured as score change from baseline to the endpoint evaluation period. The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.
Time frame: 12 months
CGI-I response rate
The CGI-I response is defined as a rating of "very much improved" or "much improved." The Clinical Global Impression of Severity and Improvement (CGI-I) is a clinician-rated tool used to measure the global impression of a treatment response in a patient's by comparing their baseline condition (i.e., before DBS system implant) with their current state.
Time frame: 12 months
Percent time in MADRS response
The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.
Time frame: 12 Months
Percent time in MADRS partial response
The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.
Time frame: 12 Months
Percent time in CGI-I partial response
The Clinical Global Impression of Severity and Improvement (CGI-I) is a clinician-rated tool used to measure the global impression of a treatment response in a patient's by comparing their baseline condition (i.e., before DBS system implant) with their current state.
Time frame: 12 Months
MADRS Response Rate
The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.
Time frame: 12 Months
Q-LES-Q score change
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is a self-report measure that assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning.
Time frame: 12 Months
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.
Of 140 interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →